COMPANY

AIM ImmunoTech

HQ: Ocala, FL source · aimimmuno.com ↗ · Southeast

Location: Ocala, FL · source · Oct 14, 2026

Profile checked Oct 10, 2026

Keywords: HIV Infections Chronic Fatigue Syndrome HIV Seropositivity Pancreatic Cancer Post COVID-19 Condition Long COVID Human Influenza Severe Acute Respiratory Syndrome Myalgic Encephalomyelitis Rintatolimod Alferon LDO poly I-poly C12U Poly I: Poly C12U (Rintatolimod) Ampligen

$10.4MRaised (2 yrs)9Trials (company is sponsor)

Timeline

2027-08 Trial start Phase 2: Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC source ↗
May 20, 2026 Raise Follow-on offering — Registered direct: $2.4M (total, as published), announced May 20, 2026. Source: company release on GlobeNewswire. source ↗
Jul 31, 2025 Raise Follow-on offering: $8M (total, as published), announced Jul 31, 2025. Source: SEC filing. source ↗
Jun 30, 2023 Trial start Phase 2: Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditions source ↗
2012-04 Trial start Phase 1/Phase 2: Safety Study of FluMist With and Without Ampligen source ↗
2005-07 Trial start Phase 2: A Randomized, Dose-ranging Study of Alferon LDO in Asymptomatic HIV+ Subjects source ↗
2004-11 Trial start Phase 2: Study of Alferon® LDO (Low Dose Oral) in Normal Volunteers source ↗
2001-05 Trial start Phase 2: The Role of Ampligen in Strategic Therapeutic Intervention (STI) of HAART source ↗
2001-05 Trial start Phase 2: Safety and Efficacy of Ampligen in the Treatment of HIV Patients Failing HAART source ↗
1998-12 Trial start Phase 3: The Study of the Safety and Efficacy of Ampligen in Chronic Fatigue Syndrome source ↗

Funding

Raised: $10.4M. Last 2 years.

May 20, 2026 Follow-on offering — Registered direct: $2.4M (total, as published), announced May 20, 2026. Source: company release on GlobeNewswire. source ↗
Jul 31, 2025 Follow-on offering: $8M (total, as published), announced Jul 31, 2025. Source: SEC filing. source ↗

Clinical trials (lead sponsor) 9

Record	Title	Phase	Status	Start	Primary completion
NCT05494697	Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC	Phase 2	Suspended	2027-08	2031-02 (estimated)
NCT00215813	Ampligen in Chronic Fatigue Syndrome	Not listed	Temporarily not available	Not listed	Not listed
NCT05592418	Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditions	Phase 2	Completed	Jun 30, 2023	Nov 17, 2023 (actual)
NCT01591473	Safety Study of FluMist With and Without Ampligen	Phase 1/Phase 2	Terminated	2012-04	2014-09 (actual)
NCT00215852	A Randomized, Dose-ranging Study of Alferon LDO in Asymptomatic HIV+ Subjects	Phase 2	Terminated	2005-07	2009-04 (actual)
NCT00215826	Study of Alferon® LDO (Low Dose Oral) in Normal Volunteers	Phase 2	Completed	2004-11	2006-04 (actual)
NCT00035893	The Role of Ampligen in Strategic Therapeutic Intervention (STI) of HAART	Phase 2	Completed	2001-05	2006-08 (actual)
NCT00035581	Safety and Efficacy of Ampligen in the Treatment of HIV Patients Failing HAART	Phase 2	Terminated	2001-05	2005-09 (actual)
NCT00215800	The Study of the Safety and Efficacy of Ampligen in Chronic Fatigue Syndrome	Phase 3	Completed	1998-12	2004-02 (actual)